N-carbamoylputrescine : An N-substituted putrescine where the N-substituent is a carbamoyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 502 |
| CHEBI ID | 17902 |
| SCHEMBL ID | 1332569 |
| MeSH ID | M0082933 |
| Synonym |
|---|
| 1-(4-aminobutyl)urea |
| CHEBI:17902 |
| C00436 |
| 6851-51-0 |
| n-carbamoylputrescine |
| AKOS005067098 |
| 4-aminobutylurea |
| unii-q40boh7f84 |
| q40boh7f84 , |
| urea, (4-aminobutyl)- |
| SCHEMBL1332569 |
| urea, n-(4-aminobutyl)- |
| DTXSID10218639 |
| (4-aminobutyl)urea |
| (4-aminobutyl)-urea |
| Q3869317 |
| EN300-146691 |
| Class | Description |
|---|---|
| N-substituted putrescine | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Pathway | Proteins | Compounds |
|---|---|---|
| Putrescine biosynthesis II | 2 | 7 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.38) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||